Line 13: |
Line 13: |
| |a1=Lateral view of the thorax demonstrates nodular lesions in the cranioventral lung fields. These lesions, some of which are cavitary, obscure the cardiac and caudal vena cava silhouette. <br><br> | | |a1=Lateral view of the thorax demonstrates nodular lesions in the cranioventral lung fields. These lesions, some of which are cavitary, obscure the cardiac and caudal vena cava silhouette. <br><br> |
| Tracheobronchial lymphadenopathy is suggested by the elevation of the trachea. | | Tracheobronchial lymphadenopathy is suggested by the elevation of the trachea. |
− | |l1= | + | |l1= Rhodococcus equi#Diagnosis |
| |q2=What is the most likely aetiologic agent? | | |q2=What is the most likely aetiologic agent? |
| |a2= | | |a2= |
Line 23: |
Line 23: |
| ''Rhod. equi'' lives in faeces and soil and is resistant to most chemical and environmental conditions. The organism is found in the intestines of many normal mammals including horses. <br><br> | | ''Rhod. equi'' lives in faeces and soil and is resistant to most chemical and environmental conditions. The organism is found in the intestines of many normal mammals including horses. <br><br> |
| Foals are most often infected by inhalation of the organism from the soil or faeces of the animals, but ingestion or umbilical entry are also possible. | | Foals are most often infected by inhalation of the organism from the soil or faeces of the animals, but ingestion or umbilical entry are also possible. |
− | |l3= | + | |l3= Rhodococcus equi#Introduction |
| |q4=What is the recommended treatment? | | |q4=What is the recommended treatment? |
| |a4=Treatment of ''Rhod. equi'' has been difficult due to the intracellular characteristics of the organism. <br><br> | | |a4=Treatment of ''Rhod. equi'' has been difficult due to the intracellular characteristics of the organism. <br><br> |
Line 31: |
Line 31: |
| Rifampin is synergistic with erythromycin and penetrates macrophages, neutrophils and caseous material readily. | | Rifampin is synergistic with erythromycin and penetrates macrophages, neutrophils and caseous material readily. |
| *Rifampin is dosed at 5mg/kg p/o bid, although some clinicians use 10mg/kg p/o sid. | | *Rifampin is dosed at 5mg/kg p/o bid, although some clinicians use 10mg/kg p/o sid. |
− | |l4=Macrolides and Lincosamides | + | |l4=Rhodococcus equi#Treatment and Control |
| </FlashCard> | | </FlashCard> |
| | | |